An expert panel at Japan's health ministry will convene on Monday to decide whether to approve a new Alzheimer's drug. It is the first drug to target a specific cause of the disease.
Approval would allow the domestic production and sale of lecanemab, which was jointly developed by Japanese firm Eisai and its US partner Biogen.
The drug is the first-ever treatment designed to slow the progression of the disease by reducing the accumulation of amyloid beta protein in the brain.
Eisai applied for the ministry's approval in January. The company says its large global clinical study shows that the treatment cut cognitive and functional decline by 27 percent after 18 months compared with a placebo group.
The US Food and Drug Administration fully approved the drug in July.
Approval would allow the domestic production and sale of lecanemab, which was jointly developed by Japanese firm Eisai and its US partner Biogen.
The drug is the first-ever treatment designed to slow the progression of the disease by reducing the accumulation of amyloid beta protein in the brain.
Eisai applied for the ministry's approval in January. The company says its large global clinical study shows that the treatment cut cognitive and functional decline by 27 percent after 18 months compared with a placebo group.
The US Food and Drug Administration fully approved the drug in July.
Similar Readings (5 items)
Japan health ministry panel approves new Alzheimer's drug
US FDA panel recommends approval of Eisai-Biogen Alzheimer's drug
Japan's health ministry to decide whether to approve new Alzheimer's drug
US approves Eisai-Biogen Alzheimer's drug
Eisai applies for approval of new Alzheimer's drug in Japan
Summary
Expert panel to decide on approval of first Alzheimer's drug targeting specific cause, lecanemab. Developed jointly by Eisai and Biogen. Reduces amyloid beta protein accumulation in the brain, slowing disease progression. Application submitted in January, shows 27% reduction in cognitive and
Statistics
129
Words1
Read CountDetails
ID: 04aa6e69-e151-422f-ab19-8c9504c1668e
Category ID: nhk
URL: https://www3.nhk.or.jp/nhkworld/en/news/20230821_05/
Date: Aug. 21, 2023
Created: 2023/08/21 07:12
Updated: 2025/12/09 00:53
Last Read: 2023/08/21 09:08